At the Maiani hospital in Tigray in the far north of Ethiopia, Kiros Girmay, a 60-year-old ex-soldier, looks despairingly at the dirty sheets on his bed.
Omnicell delivers solid third quarter financial results. Total revenues of $282 million. GAAP net income per diluted share of $0.19. Non-GAAP net income per diluted share of $0.56 ...
Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.
UPPSALA, SWEDEN / ACCESSWIRE / October 30, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 6, 1 ...